Beyond Air, Inc.

Beyond Air is a commercial-stage medical device and biopharmaceutical company that develops the LungFit® platform, a patented nitric oxide generator that produces NO from ambient air using plasma pulse technology. The company's lead product, LungFit® PH, treats persistent pulmonary hypertension of the newborn and has received regulatory approval in major markets including the United States and Europe; the company commercializes LungFit® PH directly in the U.S. through its own field sales team and via third-party distributors internationally. Beyond the core neonatal indication, the company is expanding the LungFit® platform to address viral pneumonia, bronchiolitis, and nontuberculous mycobacteria infections in children, while also developing ultra-high-concentration nitric oxide for intratumoral cancer delivery and small-molecule neuronal nitric oxide synthase inhibitors for neurological disorders through majority-owned subsidiaries, generating revenue from device sales and international distribution partnerships.